London
· Delayed Price · Currency is GBP · Price in DKK Zealand Pharma Company Description
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark.
It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs.
The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.
Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism.
The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome.
The company was incorporated in 1997 and is based in Søborg, Denmark.
| Country | Denmark |
| Founded | 1997 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 253 |
| CEO | Adam Steensberg |
Contact Details
Address: Sydmarken 11 Søborg, 2860 Denmark | |
| Phone | 45 88 77 36 00 |
| Website | zealandpharma.com |
Stock Details
| Ticker Symbol | 0NZU |
| Exchange | London Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | DKK |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Adam Steensberg | Chief Executive Officer |
| Henriette Wennicke | Chief Financial Officer |
| Ivan Moller | Chief Operating Officer |
| Mads Kronborg | Head of Investor Relations |